The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Drug resistance in cancer: Principles of emergence and prevention
Open accessAbstract
Although targeted therapy is yielding promising results in the treatment of specific cancers, drug resistance poses a problem. We develop a mathematical framework that can be used to study the principles underlying the emergence and prevention of resistance in cancers treated with targeted small-molecule drugs. We consider a stochastic dynamical system based on measurable parameters, such as the turnover rate of tumor cells and the rate at which resistant mutants are generated. We find that resistance arises mainly before the start of treatment and, for cancers with high turnover rates, combination therapy is less likely to yield an advantage over single-drug therapy. We apply the mathematical framework to chronic myeloid leukemia. Early-stage chronic myeloid leukemia was the first case to be treated successfully with a targeted drug, imatinib (Novartis, Basel). This drug specifically inhibits the BCR-ABL oncogene, which is required for progression. Although drug resistance prevents successful treatment at later stages of the disease, our calculations suggest that, within the model assumptions, a combination of three targeted drugs with different specificities might overcome the problem of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Self-renewal and solid tumor stem cells
Al-Hajj, M., & Clarke, M. F. (2004) · Oncogene · doi:10.1038/sj.onc.1207947 · Cited by 914
Virus dynamics and drug therapy
Bonhoeffer, S., May, R. M., Shaw, G. M., & Nowak, M. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6971 · Cited by 632
Errors in DNA replication as a basis of malignant changes.
Loeb, L. A., Springgate, C. F., & Battula, N. (1974) · PubMed · Cited by 619
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Chronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., & Scapozza, L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00979-3 · Cited by 373
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Cited by
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Electrospinning for drug delivery applications: A review
Luraghi, A., Peri, F., & Moroni, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.033 · Cited by 746
The mathematics of cancer: integrating quantitative models
Altrock, P. M., Liu, L. L., & Michor, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4029 · Cited by 685
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3298 · Cited by 684
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
Evolutionary dynamics of cancer in response to targeted combination therapy
Bozic, I., Reiter, J. G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y. S., Yaqubie, A., Kelly, N., Le, D. T., et al. (2013) · eLife · doi:10.7554/elife.00747 · Cited by 617
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity
Waclaw, B., Bozic, I., Pittman, M. E., Hruban, R. H., Vogelstein, B., & Nowak, M. A. (2015) · Nature · doi:10.1038/nature14971 · Cited by 486
Bell, G. (2017) · Annual Review of Ecology, Evolution, and Systematics · doi:10.1146/annurev-ecolsys-110316-023011 · Cited by 355
Functional classification of drugs by properties of their pairwise interactions
Yeh, P., Tschumi, A. I., & Kishony, R. (2006) · Nature Genetics · doi:10.1038/ng1755 · Cited by 350
Gas-Mediated Cancer Bioimaging and Therapy
Chen, L., Zhou, S.-F., Su, L., & Song, J. (2019) · ACS Nano · doi:10.1021/acsnano.9b04954 · Cited by 343
Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M. C., & Loeffler, M. (2006) · Nature Medicine · doi:10.1038/nm1487 · Cited by 334
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
Evolution in Health and Disease
(2007) · doi:10.1093/acprof:oso/9780199207466.001.0001 · Cited by 320
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Block, K. I., Gyllenhaal, C., Lowe, L., Amedei, A., Amin, A. R. M. R., Amin, A., Aquilano, K., Arbiser, J., Arreola, A., Arzumanyan, A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.007 · Cited by 300
Labi, V, & Erlacher, M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.20 · Cited by 295
Hodge, J. W., Garnett, C. T., Farsaci, B., Palena, C., Tsang, K., Ferrone, S., & Gameiro, S. R. (2013) · International Journal of Cancer · doi:10.1002/ijc.28070 · Cited by 281
Pachmann, K., Camara, O., Kavallaris, A., Krauspe, S., Malarski, N., Gajda, M., Kroll, T., Jörke, C., Hammer, U., Altendorf-Hofmann, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6523 · Cited by 280
Chemical combination effects predict connectivity in biological systems
Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275
Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy
Fu, S., Li, G., Zang, W., Zhou, X., Shi, K., & Zhai, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.012 · Cited by 266
Evolution of acquired resistance to anti-cancer therapy
Foo, J., & Michor, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.02.025 · Cited by 254
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122
Crawford, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00068 · Cited by 108
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
Komarova, N. L., Burger, J. A., & Wodarz, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409362111 · Cited by 98
“We randomly picked division and death rates chosen inside the bounds given by Messmer et al. (16) and paired them with randomly selected population sizes at treatment start chosen between the minimum and the maximum values measured in Wodarz et al. (17).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Komarova, N. L., & Wodarz, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-06-24
- Volume
- 102
- Issue
- 27
- Pages
- 9714-9719
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2094556422
- Cited by
- 414
- References
- 35
- FWCI
- 31.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.